2024
The Case | An active injection drug user with a skin rash and kidney failure
Aron A, Luciano R. The Case | An active injection drug user with a skin rash and kidney failure. Kidney International 2024, 105: 1327-1328. PMID: 38777409, DOI: 10.1016/j.kint.2024.03.009.Peer-Reviewed Original ResearchClinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta‐analysis
Cho W, Park S, Kim H, Lee M, Choi Y, Yeo S, Lee J, Koyanagi A, Jacob L, Smith L, Rahmati M, Ahmad S, Fond G, Boyer L, Rhee S, Lee S, Shin J, Woo H, Yon D. Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta‐analysis. Reviews In Medical Virology 2024, 34: e2508. PMID: 38282393, DOI: 10.1002/rmv.2508.Peer-Reviewed Original ResearchMeSH KeywordsDisease OutbreaksExanthemaFeverHIV SeropositivityHIV-1HumansMpox, MonkeypoxPublic HealthConceptsMpox virusClinical manifestationsMpox outbreakOutcomes of patientsMeta-analysisSystematic reviewNausea or vomitingMild clinical manifestationsRandom-effects modelWest African cladeAbdominal symptomsCurrent pandemic threatMild rashClinical characteristicsSexual transmissionLow mortality rateConcomitant infectionCumulative IndexWeb of SciencePooled prevalencePublic health emergencyPatientsSkin ulcersWorld Health OrganizationMortality rate
2023
Clinical manifestations of human Mpox infection: A systematic review and meta‐analysis
Yon H, Shin H, Shin J, Shin J, Shin Y, Lee J, Rhee S, Koyanagi A, Jacob L, Smith L, Lee S, Rahmati M, Ahmad S, Cho W, Yon D. Clinical manifestations of human Mpox infection: A systematic review and meta‐analysis. Reviews In Medical Virology 2023, 33: e2446. PMID: 37056203, DOI: 10.1002/rmv.2446.Peer-Reviewed Original ResearchConceptsSystematic reviewJoanna Briggs Institute quality assessment toolPooled prevalenceCochrane Database of Systematic ReviewsDatabase of Systematic ReviewsConfidence intervalsQuality assessment toolMeta-analysisRisk of biasRandom-effects modelEgger's testNewcastle-OttawaPublication biasCochrane DatabaseAssessment toolRelevant articlesNausea or vomitingGoogle ScholarEffects modelClinical presentationRespiratory symptomsPenile edemaClinical featuresClinical manifestationsSkin ulcers
2022
Acute Epstein–Barr virus infection resembling cutaneous T‐cell lymphoma
Fan R, Baker C, Glusac E, Xu M, Gru A, Cohen J. Acute Epstein–Barr virus infection resembling cutaneous T‐cell lymphoma. Journal Of Cutaneous Pathology 2022, 50: 238-242. PMID: 36349388, DOI: 10.1111/cup.14357.Peer-Reviewed Original ResearchConceptsAcute Epstein-Barr virus infectionEpstein-Barr virus infectionCutaneous T-cell lymphomaT-cell lymphomaEBV infectionVirus infectionAcute EBV infectionChronic EBV infectionInfectious mononucleosisCutaneous eruptionCutaneous manifestationsErythema multiformeViral exanthemsLymphoproliferative disordersHistopathologic featuresPrimary infectionInfectionLymphomaDisordersMononucleosisExanthemMultiforme
2021
Eosinophilia and Skin Rash in a Patient with Uncontrolled Hypertension and AKI
Aklilu A. Eosinophilia and Skin Rash in a Patient with Uncontrolled Hypertension and AKI. Kidney360 2021, 2: 2038-2039. PMID: 35419544, PMCID: PMC8986042, DOI: 10.34067/kid.0004422021.Peer-Reviewed Original ResearchA Brewing Back Pain
Pischel L, Geirsson A, Magaldi J, Martinello RA, Lee AI. A Brewing Back Pain. New England Journal Of Medicine 2021, 385: 66-72. PMID: 34192434, PMCID: PMC9273048, DOI: 10.1056/nejmcps2034802.Peer-Reviewed Original Research
2020
A 62-Year-Old Woman With Lung Cancer, Ulcerating Rash, and Rapidly Progressive Hypoxemia
Kunitomo Y, Young G, Datta R, Korn LL, Tanoue L, Gautam S. A 62-Year-Old Woman With Lung Cancer, Ulcerating Rash, and Rapidly Progressive Hypoxemia. CHEST Journal 2020, 158: e191-e196. PMID: 33036118, PMCID: PMC7533682, DOI: 10.1016/j.chest.2020.06.020.Peer-Reviewed Case Reports and Technical NotesCaution in the time of rashes and COVID-19
Vesely MD, Perkins SH. Caution in the time of rashes and COVID-19. Journal Of The American Academy Of Dermatology 2020, 83: e321-e322. PMID: 32682026, PMCID: PMC7362801, DOI: 10.1016/j.jaad.2020.07.026.Peer-Reviewed Case Reports and Technical NotesGestational outcomes in women infected by Zika virus during pregnancy in Mato Grosso do Sul, Brazil: A cross-sectional study
Sousa I, Souza C, Barbosa M, Croda J, Gonçalves C, Bernardes S, Marchioro S. Gestational outcomes in women infected by Zika virus during pregnancy in Mato Grosso do Sul, Brazil: A cross-sectional study. International Journal Of Infectious Diseases 2020, 98: 359-365. PMID: 32619757, DOI: 10.1016/j.ijid.2020.06.084.Peer-Reviewed Original ResearchConceptsCongenital Zika syndromeZIKV infectionCross-sectional studyGestational outcomesZika virusNormal-appearing infantMain clinical findingsCase fatality rateMother-infant pairsMothers of infantsQRT-PCRZika syndromeClinical caveatsClinical findingsClinical parametersFirst trimesterCongenital alterationsLive birthsLaboratory confirmationCongenital abnormalitiesFatality rateEpidemic burstsInfectionPregnancyInfants
2019
Histopathologic findings characteristic of CARD14‐associated papulosquamous eruption
Ring NG, Craiglow BG, Panse G, Antaya RJ, Ashack K, Ashack R, Faith EF, Paller AS, McNiff JM, Choate KA, Ko CJ. Histopathologic findings characteristic of CARD14‐associated papulosquamous eruption. Journal Of Cutaneous Pathology 2019, 47: 425-430. PMID: 31849081, DOI: 10.1111/cup.13633.Peer-Reviewed Original ResearchConceptsPityriasis rubra pilarisPapulosquamous eruptionHistopathologic featuresPlaque psoriasisAdult patientsFollicular pluggingClinicopathologic findingsLesional skinRetrospective studyPatientsCARD14PilarisPathogenic mutationsDermal papillaPsoriasisRange of findingsHistopathologicAcanthosisAcantholysisOrthokeratosisParakeratosisFindingsPruritic reticulation: don't ‘fiddle’ around
Salam A, Peleva E, Cowper SE, Leventhal JS. Pruritic reticulation: don't ‘fiddle’ around. Clinical And Experimental Dermatology 2019, 45: 501-504. PMID: 31762054, DOI: 10.1111/ced.14135.Peer-Reviewed Case Reports and Technical NotesThe rash in life-threatening metabolic and endocrine disorders
Mirza FN, Leventhal JS. The rash in life-threatening metabolic and endocrine disorders. Clinics In Dermatology 2019, 38: 79-85. PMID: 32197751, DOI: 10.1016/j.clindermatol.2019.10.018.Peer-Reviewed Original ResearchConceptsEndocrine disordersCutaneous manifestationsLethal complicationSkin manifestationsSystemic disordersEarly diagnosisNutritional diseasesDisordersInternal healthRashManifestationsMorbidityComplicationsAdrenalsParathyroidNeuroendocrineThyroidMortalityPancreasCliniciansDermatologistsDiseaseDiagnosisBloodThe Evolving Clinical Presentation of Acute Rejection in Facial Transplantation
Haug V, Kollar B, Obed D, Kiwanuka H, Turk M, Wo L, Tasigiorgos S, Kueckelhaus M, Riella L, Pomahac B. The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation. Facial Plastic Surgery & Aesthetic Medicine 2019, 21: 278-285. PMID: 30998810, PMCID: PMC6646986, DOI: 10.1001/jamafacial.2019.0076.Peer-Reviewed Original ResearchConceptsAcute rejectionSubtherapeutic tacrolimus levelsClinical signsRejection episodesImmunosuppressive therapySubclinical rejectionTacrolimus levelsMedical recordsOdds ratioFacial transplantationDiagnostic valueSignificant associationSingle-center cohort studyLate rejection episodesProtocol skin biopsiesSecond posttransplant yearSymptoms of rejectionTacrolimus blood levelsSecond postoperative yearReliable clinical signFull facial transplantationPostoperative yearPosttransplant yearYears posttransplantationAllograft rejectionAn Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedCD3 ComplexChildDiabetes Mellitus, Type 1Disease ProgressionDouble-Blind MethodExanthemaFemaleGlucose Tolerance TestHLA-DR3 AntigenHLA-DR4 AntigenHumansLymphocyte CountLymphopeniaMaleMiddle AgedProportional Hazards ModelsT-LymphocytesYoung AdultConceptsType 1 diabetesClinical type 1 diabetesTeplizumab groupPlacebo groupOral glucose tolerance testInsulin-producing beta cellsDouble-blind trialChronic autoimmune diseaseGlucose tolerance testRelatives of patientsRate of diagnosisHigh-risk participantsTransient lymphopeniaAdverse eventsHazard ratioHLA-DR3HLA-DR4Median timeClinical progressionAutoimmune diseasesExogenous insulinCD3 antibodyT cellsTeplizumabClinical disease
2018
Uncommon Skin Response to the Stings of Tropical Fire Ant Solenopsis geminata
Wijerathne BTB, Rathnayake GK, Dias RKS, Wickramasinghe ND, Thalgaspitiya SPB, Karunaratne AH, Agampodi SB. Uncommon Skin Response to the Stings of Tropical Fire Ant Solenopsis geminata. Wilderness And Environmental Medicine 2018, 29: 551-554. PMID: 30145121, DOI: 10.1016/j.wem.2018.06.003.Peer-Reviewed Original ResearchInflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1311-1317. PMID: 30033575, PMCID: PMC6220789, DOI: 10.1002/ajh.25228.Peer-Reviewed Original ResearchConceptsIndolent non-Hodgkin lymphomaDose-limiting toxicityNon-Hodgkin lymphomaClinical activityINHL patientsHematologic malignanciesClinical developmentGrade 3 transaminase elevationMedian progression-free survivalOral dual inhibitorAcute respiratory failureE. coli sepsisElevated liver enzymesOpen-label studyAcceptable safety profileAdvanced hematologic malignanciesDose-escalation phaseGrade 3 rashProgression-free survivalSevere adverse eventsPhase 1 studyDuration of responseFavorable clinical activityFurther clinical developmentBID cohort
2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States
Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O’Day S, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States. Journal Of Immunotherapy 2017, 40: 334-340. PMID: 29028788, PMCID: PMC5647109, DOI: 10.1097/cji.0000000000000186.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsClinical Trials as TopicDrug Resistance, NeoplasmDrug-Related Side Effects and Adverse ReactionsExanthemaFatigueFemaleHumansMaleMelanomaMiddle AgedNeoplasm MetastasisNeoplasm StagingTreatment OutcomeUnited StatesYoung AdultConceptsTreatment-related adverse eventsAdverse eventsAdvanced melanomaGrade 3/4 treatment-related adverse eventsNational Cancer Institute Common Terminology CriteriaUnresectable stage III/IV melanomaStage III/IV melanomaImmune-related response criteriaDeath-1 antibodySafety of pembrolizumabTreatment-related deathsUse of pembrolizumabCommon Terminology CriteriaObjective response rateSubcutaneous tissue disordersAccess programEvaluable patientsTerminology CriteriaCare therapyComplete responseInvestigator reviewGastrointestinal disordersDisease progressionTissue disordersBRAF inhibitorsContinued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer 2017, 113: 51-58. PMID: 29110849, DOI: 10.1016/j.lungcan.2017.08.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAfatinibAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCetuximabCohort StudiesDiarrheaDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideExanthemaFemaleGefitinibHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMutationQuinazolinesConceptsEGFR mutation-positive NSCLCEpidermal growth factor receptorMutation-positive NSCLCCell lung cancerAdverse eventsAfatinib monotherapyMedian PFSLung cancerDrug-related grade 3/4 adverse eventsFrequent drug-related adverse eventsDrug-related adverse eventsGrade 3/4 adverse eventsAddition of cetuximabIntolerable adverse eventsPhase Ib trialT790M-negative tumorsPercent of patientsPredictable safety profileAfatinib dailyGrowth factor receptorIb trialSafety profileClinical activityDry skinSeparate cohort
2016
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2016, 35: 490-497. PMID: 28029303, PMCID: PMC5455313, DOI: 10.1200/jco.2016.68.3300.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabChemoradiotherapyDisease-Free SurvivalDrug Administration ScheduleExanthemaFemaleHuman papillomavirus 16HumansInduction ChemotherapyMaleMiddle AgedNeutropeniaOropharyngeal NeoplasmsPapillomavirus InfectionsRadiotherapy DosageRemission InductionConceptsOropharyngeal squamous cell carcinomaComplete clinical responseCycle of ICPhase II trialProgression-free survivalSquamous cell carcinomaWeekly cetuximabII trialCell carcinomaPack-year smoking historyResectable squamous cell carcinomaFavorable-risk patientsPrimary end pointOverall survival rateHigh cure ratesCancer Research GroupGy of radiationRadiation doseLong-term toxicityRadiation dose reductionChemoradiation resultsICS respondersInduction chemotherapyLate sequelaeClinical response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply